- Conditions
- Alzheimer's Disease
- Interventions
- Crenezumab
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 42 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 145–168
of 4,978
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Liver Diseases, Liver Fat, Hepatic Steatosis, Nutritional and Metabolic Disease
- Interventions
- Whole Dairy
- Other
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Interventions
- Biospecimen Collection, Cisplatin, Computed Tomography, Echocardiography Test, Fludeoxyglucose F-18, Intensity-Modulated Radiation Therapy, Nivolumab, Patient Observation, Positron Emission Tomography
- Procedure · Drug · Other + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 636 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 727
- States / cities
- Fairhope, Alabama • Mobile, Alabama • Anchorage, Alaska + 462 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Metformin, Insulin, Placebo, Linagliptin, Empagliflozin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Orange, California + 39 more
- Conditions
- Cognitive Impairment Associated With Schizophrenia (CIAS)
- Interventions
- PF-04958242, placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 16
- States / cities
- Garden Grove, California • Oceanside, California • Orange, California + 11 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- TAK-788
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 28 more
- Conditions
- Autism Spectrum Disorder, Obesity, Childhood, Autism
- Interventions
- PBT-A, Health Education (HE)
- Behavioral
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Obesity, Overweight
- Interventions
- Naltrexone SR 32 mg/ bupropion SR 360 mg/ day, Placebo, Intensive group lifestyle modification counseling
- Drug · Behavioral
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 793 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 9
- States / cities
- La Jolla, California • Denver, Colorado • Gainesville, Florida + 5 more
- Conditions
- Interstitial Cystitis, Bladder Pain Syndrome
- Interventions
- VNX001, Placebo, Lidocaine, Heparin
- Drug
- Lead sponsor
- Vaneltix Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Escondido, California • Los Angeles, California • Newport Beach, California + 10 more
- Conditions
- Advanced Non Small Cell Lung Cancer
- Interventions
- DV281, Breath Actuated Nebulizer, DV281 (RP2D), Approved Anti-PD-1 Inhibitor
- Drug · Device
- Lead sponsor
- Dynavax Technologies Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 6
- States / cities
- La Jolla, California • Santa Monica, California • Minneapolis, Minnesota + 3 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- Hydroxychloroquine, Placebo
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 12
- States / cities
- Los Angeles, California • San Diego, California • Atlanta, Georgia + 5 more
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Loss of Heterozygosity, Lung Non-Small Cell Squamous Carcinoma, Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
- Interventions
- Rucaparib
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Not listed
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 950
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 630 more
- Conditions
- Dystonia
- Interventions
- Not listed
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3,265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2020
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Fountain Valley, California + 26 more
- Conditions
- Germ Cell Tumor, Metachronous Malignant Neoplasm, Seminoma, Stage I Testicular Cancer AJCC v8, Stage IA Testicular Cancer AJCC v8, Stage IB Testicular Cancer AJCC v8, Stage IS Testicular Cancer AJCC v8
- Interventions
- Biomarker Analysis, Blood Product Collection
- Other · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 956 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 412
- States / cities
- Gilbert, Arizona • Kingman, Arizona • Tucson, Arizona + 261 more
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Interventions
- BH-30643, BH-30643 combo therapy with Carboplatin/Pemetrexed
- Drug
- Lead sponsor
- BlossomHill Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 675 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Irvine, California • La Jolla, California + 18 more
- Conditions
- Rhematoid Arthritis
- Interventions
- Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate
- Drug · Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 60
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Covina, California + 47 more
- Conditions
- Schizophrenia Spectrum & Other Psychotic Disorders
- Interventions
- Patient Aligned Care Team (PACT)
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 331 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 3
- States / cities
- San Diego, California • West Los Angeles, California • Las Vegas, Nevada
- Conditions
- Psoriatic Arthritis, Overweight or Obesity
- Interventions
- Tirzepatide
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 53
- States / cities
- Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 48 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Tocilizumab (TCZ), Methotrexate (MTX), Placebo (PBO)
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 718 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 155
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 126 more
- Conditions
- Multiple Sclerosis
- Interventions
- Frexalimab, Placebo, MRI contrast-enhancing agents
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 943 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 79
- States / cities
- Homewood, Alabama • Scottsdale, Arizona • Berkeley, California + 68 more
- Conditions
- Age Related Macular Degeneration (AMD)
- Interventions
- GT005
- Genetic
- Lead sponsor
- Gyroscope Therapeutics Limited
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 22
- States / cities
- Poway, California • Durango, Colorado • Gainesville, Florida + 18 more
- Conditions
- B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
- Interventions
- Biospecimen Collection, Calaspargase Pegol, Levocarnitine, Pegaspargase, Quality-of-Life Assessment
- Procedure · Drug · Dietary Supplement + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 15 Years to 40 Years
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 225
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Kingman, Arizona + 149 more
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis
- Interventions
- Placebo, PF-06865571, PF-05221304
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 256 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 184
- States / cities
- Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 101 more
- Conditions
- Fibromyalgia
- Interventions
- AVACEN Thermal Exchange System
- Device
- Lead sponsor
- Avacen, Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- La Jolla, California